STOCK TITAN
  1. Home
  2. Sec-filings
  3. ORMP
  4. [Form 4] ORAMED PHARMACEUTICALS INC. Insider Trading Activity

ORAMED (NASDAQ: ORMP) CFO executes pre-planned sale of 73,360 shares

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

ORAMED PHARMACEUTICALS INC. Chief Financial Officer Avraham Gabay reported an open-market sale of 73,360 shares of common stock on July 1, 2026 at a weighted average price of $4.5085 per share. The transaction was executed as a planned sale under a Rule 10b5-1 trading plan adopted on March 30, 2026, indicating it was pre-arranged rather than timed discretionarily. Following this sale, Gabay directly holds 671,785 shares, showing he retains a substantial equity position in the company.

Positive

  • None.

Negative

  • None.
Insider Gabay Avraham
Role Chief Financial Officer
Sold 73,360 shs ($331K)
Type Security Shares Price Value
Sale Common Stock 73,360 $4.5085 $331K
Holdings After Transaction: Common Stock — 671,785 shares (Direct, null)
Footnotes (1)
  1. Represents shares sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 30, 2026. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.255 to $4.750, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
Shares sold 73,360 shares Open-market sale on July 1, 2026
Average sale price $4.5085 per share Weighted average across multiple trades
Price range $4.255–$4.750 per share Range of individual sale prices
Shares owned after sale 671,785 shares Direct holdings following transaction
Net shares sold 73,360 shares Net-sell direction in transaction summary
Rule 10b5-1 trading plan regulatory
"Represents shares sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 30, 2026."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
open-market sale financial
"transaction_action: open-market sale"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Form 4 regulatory
"INSIDER FILING DATA (Form 4):"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Gabay Avraham
(Last)(First)(Middle)
1185 AVENUE OF THE AMERICAS
THIRD FLOOR
(Street)
NEW YORK NEW YORK 10036
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
ORAMED PHARMACEUTICALS INC. [ ORMP ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Financial Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock07/01/2026S73,360(1)D$4.5085(2)671,785D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents shares sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 30, 2026.
2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.255 to $4.750, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
/s/ Avraham Gabay07/02/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did ORAMED (ORMP) disclose for Avraham Gabay?

ORAMED disclosed that CFO Avraham Gabay sold 73,360 shares of common stock in an open-market transaction. The sale occurred at a weighted average price of $4.5085 per share and was executed under a pre-arranged Rule 10b5-1 trading plan.

At what price did ORAMED CFO Avraham Gabay sell his ORMP shares?

The weighted average sale price was $4.5085 per share, with individual trades executed between $4.255 and $4.750. This range reflects multiple transactions aggregated into one reported figure for the Form 4 disclosure of the CFO’s open-market sale.

How many ORMP shares does ORAMED CFO Avraham Gabay hold after this sale?

After selling 73,360 shares, CFO Avraham Gabay directly holds 671,785 ORMP common shares. This remaining stake indicates he continues to maintain a sizable ownership position in ORAMED PHARMACEUTICALS INC. following the reported open-market transaction.

Was the ORAMED CFO’s ORMP share sale made under a Rule 10b5-1 plan?

Yes. The filing states the 73,360 shares were sold under a Rule 10b5-1 trading plan adopted on March 30, 2026. Such plans are pre-arranged, reducing the significance of trade timing as an indicator of management’s current outlook.

What does the Form 4 reveal about ORAMED CFO’s net trading direction in ORMP stock?

The Form 4 shows a net sale of 73,360 shares, classified as an open-market sale. There were no reported purchases, option exercises, gifts, or tax withholdings in this filing, so the overall activity reflects a single selling transaction.